0001655759-25-000139 | 10-Q | XBRL Viewer

Label	Element	Value
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	$ 15,100,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	25,100,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	39,200,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	44,100,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	3,800,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	1,700,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	10,300,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	3,000,000.0
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,500,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	1,700,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	5,100,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,900,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	1,700,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	200,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,600,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	300,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	900,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,500,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,000,000.0
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	4,100,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	0
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	9,500,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	0
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	13,200,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	800,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	0
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	2,500,000
Research And Development Expense, Program Specific	arvn_ResearchAndDevelopmentExpenseProgramSpecific	0
Required Milestone Payments	arvn_RequiredMilestonePayments	3,000,000
Required Milestone Payments	arvn_RequiredMilestonePayments	1,500,000
Collaborative Arrangement, Rights And Obligations, Milestone Payment	arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment	5,000,000
Collaborative Arrangement, Rights And Obligations, Milestone Payment	arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment	$ 15,000,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants	arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants	170,365
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period	arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod	$ 14,900,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period	arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod	11,400,000
Accrued General And Administrative And Commercial, Current	arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent	3,200,000
Accrued General And Administrative And Commercial, Current	arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent	5,100,000
Debt Instrument Loan Forgiveness	arvn_DebtInstrumentLoanForgiveness	1,000,000.0
Research And Development Expense, Non-Program Specific	arvn_ResearchAndDevelopmentExpenseNonProgramSpecific	11,100,000
Research And Development Expense, Non-Program Specific	arvn_ResearchAndDevelopmentExpenseNonProgramSpecific	13,500,000
Research And Development Expense, Non-Program Specific	arvn_ResearchAndDevelopmentExpenseNonProgramSpecific	25,000,000.0
Research And Development Expense, Non-Program Specific	arvn_ResearchAndDevelopmentExpenseNonProgramSpecific	29,600,000
Accrued Research And Development Expense Current	arvn_AccruedResearchAndDevelopmentExpenseCurrent	16,200,000
Accrued Research And Development Expense Current	arvn_AccruedResearchAndDevelopmentExpenseCurrent	$ 25,900,000
Stock Issued During Period, Shares, Exercise Of Warrants	arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants	3,422,186
Annual License Fee Payment	arvn_AnnualLicenseFeePayment	$ 100,000
Proceeds From Maturities Of Marketable Securities	arvn_ProceedsFromMaturitiesOfMarketableSecurities	437,500,000
Proceeds From Maturities Of Marketable Securities	arvn_ProceedsFromMaturitiesOfMarketableSecurities	$ 326,400,000
Debt Instrument Interest Payments Term	arvn_DebtInstrumentInterestPaymentsTerm	60 months
Number of Licensed Products	arvn_NumberOfLicensedProducts	2
Stock Issued During Period, Shares, Warrants Exercised	arvn_StockIssuedDuringPeriodSharesWarrantsExercised	3,400,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants	arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants	255,611
Maximum Aggregate Offering Price Of Common Stock	arvn_MaximumAggregateOfferingPriceOfCommonStock	$ 262,800,000
Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares	arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	500,000
Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares	arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	5,300,000
Payments For Collaboration	arvn_PaymentsForCollaboration	14,950,000
Cash, Cash Equivalents, Restricted Cash and Marketable Securities	arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities	$ 861,200,000

Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Accounts receivable related to collaborations
Additions	$ 0.1	$ 1.8
Payments received	(5.3)	0.0
Accounts payable related to collaborations
Beginning balance	5.4	13.1
Additions	29.5	29.2
Payments made	(24.8)	(26.1)
Ending balance	10.1	16.2
Contract assets: Collaboration contract asset
Additions	0.0	3.0
Amortization	(3.7)	(1.7)
Contract liabilities: Deferred revenue
Additions to collaboration agreements	0.0	130.0
Revenue recognized from new collaborations	$ 0.0	$ (23.7)

Research Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2025	Dec. 31, 2024	May 31, 2024
Research Collaboration And License Agreements [Line Items]
Collaboration agreement direct and incremental costs incurred	$ 12.9
Collaboration contract asset and other assets	$ 12.9	$ 8.1
Contingent payments			$ 1,010.0

Print Document
Details Research Collaboration and License Agreements - Additional Information (Details) Research Collaboration and License Agreements - Summary of Contract Balances (Details) Uncategorized Uncategorized Items - arvn-20250630_htm.xml All Reports